Global Peptide Therapeutics Market & Clinical Trials Insight 2028
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
Global Peptide Therapeutics Market & Clinical Trials Insight 2028 Report findings:
Till date, more than 200 peptide based therapeutics have gained approval from regulatory bodies. The most common indications for peptides are oncology, endocrinology, and metabolic diseases. Other target areas of peptides that have gained attention include gastroenterology, cardiovascular diseases, dermatology, bone diseases, and sexual dysfunction. The robust response of peptide therapeutics in the market has propelled the further research activities in this domain. Currently, more than 800 clinical trials are ongoing in global peptide therapeutics market which suggests promising future of peptide therapeutics in the forthcoming years.
The global peptide therapeutics market is both competitive along with being fragmented on account of the presence of several international and also domestic industry players. Such industry players have utilized an assorted innovative strategies for being at the top along with sufficing to the burgeoning requirement of the esteemed clients including geographic expansions, collaborations, joint ventures, new product launches, partnerships, contracts, and much more. For instance, Bicycle Therapeutics has entered into strategic collaboration with Genentech to discover, develop and commercialize novel Bicycle®-based immuno-oncology therapies. Further, Fusion Pharmaceuticals also enter into collaboration with Pepscan to discover, novel, peptide-based radiopharmaceuticals for the management of solid tumors.
By therapeutic indication, cancer peptide occupies more than 25% share in the global market. Several peptide based drugs including Firmagon, Eligard, Velcade, Zoladex, Cosmegen, Sandostatin, Mepact, and others have entered the market and have shown robust response rate. More recently, peptide cancer vaccine namely Riavax have also gained approval in South Korea for the treatment of locally advanced or metastatic pancreatic cancer. The promising sales of these drugs are driving this segment during the forecast period. Furthermore, surge in prevalence of cancer and unmet need of cost effective targeted drugs are also anticipated to propel the growth of cancer peptide drugs during the forecast period.
It is analyzed that the future holds an extensive place for peptides in addressing the greatest of medical challenge due to their capability of being adapted and modified to achieve the desired action. There is immense scope for the development of new peptides with protein fragmentation along with alternative routes of administration and improved oral bioavailability. They will also be used to address the currently undruggable targets in the coming years. Keeping the clinical pipeline in consideration, it is expected that the global peptide therapeutics market will surpass US$ 75 Billion by 2028. In addition to above mentioned factors, rising geriatric population and associated increase in chronic disease will also drive the growth of market.
The report provides detailed review of the overall market landscape of peptide-based therapies, including information on their current phase of development (marketed, clinical, preclinical and discovery), type of peptide, route of administration, and key therapeutic area. The report also gives insightful market assessment summary, highlighting the clinical and commercial attractiveness of pipeline molecules. This report forecasts revenue growth at global levels and provides an analysis of the latest trends and opportunities. The major companies mentioned in the report include Amgen, GlaxoSmithKline, NovoNordisk, ImmunoCellular Therapeutics, Lonza, PeptiDream and others.
Global Peptide Therapeutics Market & Clinical Trials Insight 2028 Report findings:
- Global Peptide Therapeutics Market Opportunity > USD 75 billion by 2028
- Global Peptide Therapeutics Clinical Trials Insight by Company, Indication & Phase
- Peptide Therapeutics in Clinical trials: > 800 Drugs
- Peptide Therapeutics Commercially Available In Market: > 200 Drugs
- Global Peptide Therapeutics Clinical Trials Insight By Peptide Type: Glucagon-like Peptides, Cyclic Peptides, Glycopeptides, Oligopeptides, Lipopeptides, Dipeptides, Opioid, Depsipeptides, Neuropeptides, Natriuretic, Bicyclic Peptides
Till date, more than 200 peptide based therapeutics have gained approval from regulatory bodies. The most common indications for peptides are oncology, endocrinology, and metabolic diseases. Other target areas of peptides that have gained attention include gastroenterology, cardiovascular diseases, dermatology, bone diseases, and sexual dysfunction. The robust response of peptide therapeutics in the market has propelled the further research activities in this domain. Currently, more than 800 clinical trials are ongoing in global peptide therapeutics market which suggests promising future of peptide therapeutics in the forthcoming years.
The global peptide therapeutics market is both competitive along with being fragmented on account of the presence of several international and also domestic industry players. Such industry players have utilized an assorted innovative strategies for being at the top along with sufficing to the burgeoning requirement of the esteemed clients including geographic expansions, collaborations, joint ventures, new product launches, partnerships, contracts, and much more. For instance, Bicycle Therapeutics has entered into strategic collaboration with Genentech to discover, develop and commercialize novel Bicycle®-based immuno-oncology therapies. Further, Fusion Pharmaceuticals also enter into collaboration with Pepscan to discover, novel, peptide-based radiopharmaceuticals for the management of solid tumors.
By therapeutic indication, cancer peptide occupies more than 25% share in the global market. Several peptide based drugs including Firmagon, Eligard, Velcade, Zoladex, Cosmegen, Sandostatin, Mepact, and others have entered the market and have shown robust response rate. More recently, peptide cancer vaccine namely Riavax have also gained approval in South Korea for the treatment of locally advanced or metastatic pancreatic cancer. The promising sales of these drugs are driving this segment during the forecast period. Furthermore, surge in prevalence of cancer and unmet need of cost effective targeted drugs are also anticipated to propel the growth of cancer peptide drugs during the forecast period.
It is analyzed that the future holds an extensive place for peptides in addressing the greatest of medical challenge due to their capability of being adapted and modified to achieve the desired action. There is immense scope for the development of new peptides with protein fragmentation along with alternative routes of administration and improved oral bioavailability. They will also be used to address the currently undruggable targets in the coming years. Keeping the clinical pipeline in consideration, it is expected that the global peptide therapeutics market will surpass US$ 75 Billion by 2028. In addition to above mentioned factors, rising geriatric population and associated increase in chronic disease will also drive the growth of market.
The report provides detailed review of the overall market landscape of peptide-based therapies, including information on their current phase of development (marketed, clinical, preclinical and discovery), type of peptide, route of administration, and key therapeutic area. The report also gives insightful market assessment summary, highlighting the clinical and commercial attractiveness of pipeline molecules. This report forecasts revenue growth at global levels and provides an analysis of the latest trends and opportunities. The major companies mentioned in the report include Amgen, GlaxoSmithKline, NovoNordisk, ImmunoCellular Therapeutics, Lonza, PeptiDream and others.
1. INTRODUCTION TO PEPTIDE THERAPEUTICS
1.1 Overview of Peptide Therapeutics
1.2 Historical Perspective of Peptide Therapeutics
1.3 Classification Of Anti Cancer Peptides
2. TARGETS FOR THERAPEUTIC PEPTIDES
2.1 Signal Transduction Pathways
2.2 Cell Cycle Regulation
2.3 Cell Death Pathways
2.4 Tumor Suppressor Protein
2.5 Transcription Factors
3. GLOBAL PEPTIDE THERAPEUTICS MARKET OVERVIEW
4. GLOBAL PEPTIDE THERAPEUTICS CLINICAL TRIALS OVERVIEW
4.1 By Company
4.2 By Country
4.3 By Indication
4.4 By Patient Segment
4.5 By Phase
5. INSULIN CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
5.1 Research
5.2 Preclinical
5.3 Phase-I
5.4 Phase-II
5.5 Phase-II/III
5.6 Phase-III
5.7 Preregistration
5.8 Registered
5.9 Marketed
6. GLUCAGON-LIKE PEPTIDES CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
6.1 Research
6.2 Preclinical
6.3 Phase-I
6.4 Phase-I/II
6.5 Phase-II
6.6 Phase-III
6.7 Preregistration
6.8 Marketed
7. PEPTIDES CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
7.1 Research
7.2 Preclinical
7.3 Clinical Phase Unknown
7.4 Phase-I
7.5 Phase-I/II
7.6 Phase-II
7.7 Phase-II/III
7.8 Phase-III
7.9 Preregistration
7.12 Registered
7.11 Marketed
8. CYCLIC PEPTIDES CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
8.1 Research
8.2 Preclinical
8.3 Clinical Phase Unknown
8.4 Phase-I
8.5 Phase-II
8.6 Phase-III
8.7 Marketed
9. MULTIPLE PEPTIDES CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
9.1 Research
9.2 Preclinical
9.3 Phase-I
9.4 Phase-I/II
9.5 Phase-II
9.6 Phase-III
9.7 Preregistration
9.8 Registered
9.9 Marketed
10. GLYCOPEPTIDES CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
10.1 Research
10.2 Preclinical
10.3 Phase-I
10.4 Phase-I/II
10.5 Preregistration
10.6 Marketed
11. OLIGOPEPTIDES CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
11.1 Preclinical
11.2 Phase-I/II
11.3 Phase-II
11.4 Phase-II/III
11.5 Phase-III
11.6 Registered
11.7 Marketed
12. LIPOPEPTIDES CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
12.1 Research
12.2 Phase-II
12.3 Marketed
13. DIPEPTIDES CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
13.1 Research
13.2 Phase-I
13.3 Phase-II
13.4 Phase-III
13.5 Registered
13.6 Marketed
14. OPIOID PEPTIDES CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
14.1 Research
14.2 Preclinical
14.3 Phase-I/II
14.4 Preregistration
14.5 Registered
14.6 Marketed
15. DEPSIPEPTIDES CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
15.1 Preclinical
15.2 Phase-II
15.3 Registered
15.4 Marketed
16. NEUROPEPTIDES CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
16.1 Research
16.2 Preclinical
16.3 Phase-I/II
16.4 Phase-II
16.5 Marketed
17. NATRIURETIC PEPTIDES CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
17.1 Phase-II
17.2 Marketed
18. BICYCLIC PEPTIDES CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
18.1 Preclinical
19. COMPETITIVE LANDSCAPE
19.1 Amgen
19.2 Amylin Pharmaceuticals
19.3 Apitope Technology
19.4 BioPartners
19.5 BiondVax Pharmaceuticals Ltd
19.6 Boehringer Ingelheim
19.7 Circassia
19.8 Corden Pharma (Peptisyntha)
19.9 Eli Lily
19.10 Galena Biopharmaceuticals
19.11 GlaxoSmithKline
19.12 Hyperion Therapeutics
19.13 ImmunoCellular Therapeutics
19.14 Ipsen
19.15 Lonza
19.16 Merck
19.17 NovoNordisk
19.18 Par Pharmaceuticals
19.19 PeptiDream
19.20 Roche
19.21 Sanofi
19.22 Tarix Pharmaceuticals
1.1 Overview of Peptide Therapeutics
1.2 Historical Perspective of Peptide Therapeutics
1.3 Classification Of Anti Cancer Peptides
2. TARGETS FOR THERAPEUTIC PEPTIDES
2.1 Signal Transduction Pathways
2.2 Cell Cycle Regulation
2.3 Cell Death Pathways
2.4 Tumor Suppressor Protein
2.5 Transcription Factors
3. GLOBAL PEPTIDE THERAPEUTICS MARKET OVERVIEW
4. GLOBAL PEPTIDE THERAPEUTICS CLINICAL TRIALS OVERVIEW
4.1 By Company
4.2 By Country
4.3 By Indication
4.4 By Patient Segment
4.5 By Phase
5. INSULIN CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
5.1 Research
5.2 Preclinical
5.3 Phase-I
5.4 Phase-II
5.5 Phase-II/III
5.6 Phase-III
5.7 Preregistration
5.8 Registered
5.9 Marketed
6. GLUCAGON-LIKE PEPTIDES CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
6.1 Research
6.2 Preclinical
6.3 Phase-I
6.4 Phase-I/II
6.5 Phase-II
6.6 Phase-III
6.7 Preregistration
6.8 Marketed
7. PEPTIDES CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
7.1 Research
7.2 Preclinical
7.3 Clinical Phase Unknown
7.4 Phase-I
7.5 Phase-I/II
7.6 Phase-II
7.7 Phase-II/III
7.8 Phase-III
7.9 Preregistration
7.12 Registered
7.11 Marketed
8. CYCLIC PEPTIDES CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
8.1 Research
8.2 Preclinical
8.3 Clinical Phase Unknown
8.4 Phase-I
8.5 Phase-II
8.6 Phase-III
8.7 Marketed
9. MULTIPLE PEPTIDES CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
9.1 Research
9.2 Preclinical
9.3 Phase-I
9.4 Phase-I/II
9.5 Phase-II
9.6 Phase-III
9.7 Preregistration
9.8 Registered
9.9 Marketed
10. GLYCOPEPTIDES CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
10.1 Research
10.2 Preclinical
10.3 Phase-I
10.4 Phase-I/II
10.5 Preregistration
10.6 Marketed
11. OLIGOPEPTIDES CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
11.1 Preclinical
11.2 Phase-I/II
11.3 Phase-II
11.4 Phase-II/III
11.5 Phase-III
11.6 Registered
11.7 Marketed
12. LIPOPEPTIDES CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
12.1 Research
12.2 Phase-II
12.3 Marketed
13. DIPEPTIDES CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
13.1 Research
13.2 Phase-I
13.3 Phase-II
13.4 Phase-III
13.5 Registered
13.6 Marketed
14. OPIOID PEPTIDES CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
14.1 Research
14.2 Preclinical
14.3 Phase-I/II
14.4 Preregistration
14.5 Registered
14.6 Marketed
15. DEPSIPEPTIDES CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
15.1 Preclinical
15.2 Phase-II
15.3 Registered
15.4 Marketed
16. NEUROPEPTIDES CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
16.1 Research
16.2 Preclinical
16.3 Phase-I/II
16.4 Phase-II
16.5 Marketed
17. NATRIURETIC PEPTIDES CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
17.1 Phase-II
17.2 Marketed
18. BICYCLIC PEPTIDES CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
18.1 Preclinical
19. COMPETITIVE LANDSCAPE
19.1 Amgen
19.2 Amylin Pharmaceuticals
19.3 Apitope Technology
19.4 BioPartners
19.5 BiondVax Pharmaceuticals Ltd
19.6 Boehringer Ingelheim
19.7 Circassia
19.8 Corden Pharma (Peptisyntha)
19.9 Eli Lily
19.10 Galena Biopharmaceuticals
19.11 GlaxoSmithKline
19.12 Hyperion Therapeutics
19.13 ImmunoCellular Therapeutics
19.14 Ipsen
19.15 Lonza
19.16 Merck
19.17 NovoNordisk
19.18 Par Pharmaceuticals
19.19 PeptiDream
19.20 Roche
19.21 Sanofi
19.22 Tarix Pharmaceuticals
LIST OF FIGURES
Figure 1-1: Classification of Anti-Cancer Peptides
Figure 2-1: Therapeutic Peptides Based on Their Biological Targets
Figure 2-2: MAPK Signaling Pathways
Figure 2-3: Cell Cycle in Eukaryotic
Figure 2-4: Cell Death Pathways
Figure 2-5: Features of Bcl-2 Family Proteins Including Anti-Apoptotic & Pro-Apoptotic
Figure 3-1: Global – Peptide Therapeutic Market (US$ Billion), 2020 - 2028
Figure 3-2: Global – Total Peptide Therapeutic Market Size vs. Cancer Peptide Therapeutic Market (US$ Billion), 2021
Figure 3-3: Global – Cancer Peptide Market Share in Total Peptide Market (%), 2021
Figure 3-4: Global – Cancer Peptide Drugs Market Size (US$ Billion), 2020 - 2028
Figure 4-1: Global - Peptide Drug Clinical Pipeline by Company (Number of Drugs), 2022 till 2028
Figure 4-2: Global - Peptide Drug Clinical Pipeline by Country (Number of Drugs), 2022 till 2028
Figure 4-3: Global - Peptide Drug Clinical Pipeline by Indication (Number of Drugs), 2022 till 2028
Figure 4-4: Global - Peptide Drug Clinical Pipeline by Patient Segment (Number of Drugs), 2022 till 2028
Figure 4-5: Global - Peptide Drug Clinical Pipeline by Phase (Number of Drugs), 2022 till 2028
Figure 1-1: Classification of Anti-Cancer Peptides
Figure 2-1: Therapeutic Peptides Based on Their Biological Targets
Figure 2-2: MAPK Signaling Pathways
Figure 2-3: Cell Cycle in Eukaryotic
Figure 2-4: Cell Death Pathways
Figure 2-5: Features of Bcl-2 Family Proteins Including Anti-Apoptotic & Pro-Apoptotic
Figure 3-1: Global – Peptide Therapeutic Market (US$ Billion), 2020 - 2028
Figure 3-2: Global – Total Peptide Therapeutic Market Size vs. Cancer Peptide Therapeutic Market (US$ Billion), 2021
Figure 3-3: Global – Cancer Peptide Market Share in Total Peptide Market (%), 2021
Figure 3-4: Global – Cancer Peptide Drugs Market Size (US$ Billion), 2020 - 2028
Figure 4-1: Global - Peptide Drug Clinical Pipeline by Company (Number of Drugs), 2022 till 2028
Figure 4-2: Global - Peptide Drug Clinical Pipeline by Country (Number of Drugs), 2022 till 2028
Figure 4-3: Global - Peptide Drug Clinical Pipeline by Indication (Number of Drugs), 2022 till 2028
Figure 4-4: Global - Peptide Drug Clinical Pipeline by Patient Segment (Number of Drugs), 2022 till 2028
Figure 4-5: Global - Peptide Drug Clinical Pipeline by Phase (Number of Drugs), 2022 till 2028
